Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Revokes Emergency Authorization On Ebola, Zika Tests

Executive Summary

Emergency Use Authorizations on two Ebola tests and one for the Zika virus have been revoked by the US agency because it cleared the tests via more permanent pathways.

You may also be interested in...

US Agencies Join Forces To Accelerate Development Of Emergency Diagnostics

Three US health-care agencies – FDA, the Centers for Disease Control and Prevention, and the Centers for Medicare and Medicaid Services – set up a “Tri-Agency Task Force for Emergency Diagnostics” to rapidly push effective emergency-use tests into the field when outbreaks of Ebola, Zika, Influenza or similar health threats occur in the US or globally.

Industry And Investors Ponder Legacy Of Theranos Scandal

What lessons can be learned from the conviction of Theranos founder Elizabeth Holmes, found guilty on four counts of investor fraud in a US court on 4 January?

Attorneys Mull Takeaways From Conviction Of Theranos Founder Holmes

Elizabeth Holmes has been convicted on four counts of investor fraud. Two attorneys who followed the case spoke to Medtech Insight about what happened – and what it could mean for industry as a whole.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts